Raj Chovatiya, MD, PhD

Matthew Zirwas, MD, shares goals of therapy for a patient with AD.

Expert dermatologists address the clinical implications of boxed warnings of topical treatments in AD.

Matthew Zirwas, MD, and Omar Noor, MD, comment on their own experience of time to response with topical and systemic treatments of AD.

Peter A. Lio, MD, discusses the durability of topical treatments in AD, including steroids, calcineurin inhibitors, and JAK inhibitors.

Experts discuss long-term efficacy data for topical medications for the treatment of AD.

Matthew Zirwas, MD, and Omar Noor, MD, review a patient scenario where AD disease activity is limited but in difficult to treat locations.

Peter A. Lio, MD, shares his approach to presenting treatment alternatives to patients who want to stop using long-term steroids for treatment of AD.

Adelaide A. Hebert, MD, comments on the need for nondermatologist education on the basics of skin disease care.

Expert dermatologists discuss the durability of long-term use of topical steroids for treatment of atopic dermatitis.

Adelaide A. Hebert, MD, reviews the use of long-term steroids for treatment of atopic dermatitis.

Shawn Kwatra, MD, and Sarina B. Elmariah, MD, PhD, share final pearls of wisdom for other physicians taking care of patients with prurigo nodularis (PN).

Experts in dermatology discuss unmet needs in prurigo nodularis (PN) and the importance of addressing those needs for disease management.

Drs Raj Chovatiya, Shawn Kwatra, and Sarina B. Elmariah review exciting new therapies in the treatment landscape of PN.

Experts in dermatology discuss which disease characteristics play the biggest role in influencing treatment choice or change of treatment from the perspective of a patient with atopic dermatitis.

A panel of expert dermatologists comments on newly approved and traditional treatment options, addressing how they target inflammation and the pathophysiology of atopic dermatitis (AD).

Experts in dermatology share thoughts on the need for additional investigative research of prurigo nodularis in order to better treat patients.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss potential challenges to the adoption of dupilumab in the treatment of PN.

Experts in dermatology discuss ideal candidates for dupilumab.

Drs Raj Chovatiya, Shawn Kwatra, and Sarina B. Elmariah review PRIME and PRIME 2 phase 3 studies of dupilumab for treatment of PN.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss a newly approved drug, dupilumab, for the treatment of PN.

Raj Chovatiya, MD, PhD, reviews the limitations of topical treatments when managing PN.

Sarina B. Elmariah, MD, PhD, talks about less commonly used treatments for patients with prurigo nodularis (PN).

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD; provide an overview of therapies currently available for treating PN.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD; share guideline resources that physicians turn to when treating PN.

Experts in dermatology discuss treatment goals for PN and how they can differ based on severity of itching and nodules.

Dr. Raj Chovatiya discusses how recent approvals will influence the way in which he and other dermatologists will manage atopic dermatitis going forward.

Dr. Raj Chovatiya shares his thoughts on the recent approval of ruxolitinib for treatment of vitiligo and where he might use it, either alone or in combination with other vitiligo treatments.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, share the importance of having multiple health care providers across the disciplines when diagnosing and treating prurigo nodularis (PN).

Experts in dermatology examine a patient’s road to diagnosis of prurigo nodularis (PN), focusing on the symptoms that bring them to the initial specialist visit.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss the pathophysiology on PN and the role of type 1 inflammation in the disease.